Breaking News

Par Appoints CEO

April 1, 2014

Coughlin to head global manufacturing activities

Terrance J. Coughlin has been named chief operating officer of Par Pharmaceutical Companies, Inc. Mr. Coughlin will be responsible for global manufacturing activities and R&D efforts, as well as the new product selection process. 
 
Mr. Coughlin joins the company from Glenmark Generics, Inc., where he most recently served as president and chief executive officer, and prior to that, served as president. Mr. Coughlin had overall responsibility for the North American, Western European and Eastern European generics businesses, as well as the global API business and generics operations in India. Mr. Coughlin also served as senior vice president at Dr. Reddy's Laboratories, and was responsible for global key accounts for bulk active ingredient operations for North America and Europe. 
 
"Having worked with Terry, I know personally that he is a talented and capable senior manager with a proven track record of success," said Paul V. Campanelli, chief executive officer of Par Pharmaceutical Companies. "Terry's more than 25 years experience in the pharmaceutical industry extends from API to finished dosage, and from R&D to sales and marketing.  He has managed businesses, including manufacturing facilities, in the U.S. and abroad.  Terry's breadth of experience will serve Par well and I am excited to welcome him to our company." 
 
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks